Indonesia Expands Adult Measles Vaccination to Shield Healthcare Workers Amid Outbreak
In a strategic move to curb an ongoing outbreak, the Indonesian Food and Drug Authority (BPOM) has expanded the approved indications for Measles-Rubella (MR) vaccines to include adult populations. Following this regulatory update, the Ministry of Health (Kemenkes) announced on April 8, 2026, that it is strengthening outbreak control by expanding vaccine use for adults.
The initiative specifically targets frontline healthcare workers who face a significantly higher risk of infection even as treating patients. L. Rizka Andalusia, Director General of Pharmacy and Medical Devices, emphasized that protecting these high-risk individuals is critical during the current public health emergency. This effort focuses on prioritizing vaccinations in 14 provinces reporting the highest case numbers.
The Ministry of Health has identified a total requirement of approximately 290,000 doses for priority adult groups. This target includes 39,212 medical personnel and 223,150 healthcare workers within the high-incidence provinces. The government is vaccinating 28,321 general practitioners and dentists currently undergoing internships across the country.
BPOM Head Taruna Ikrar confirmed that the approval for MR, MMR, and single measles vaccines for adults followed a rigorous review process. The authorized vaccines include those produced by Bio Farma/Serum Institute of India, GlaxoSmithKline (GSK), and Merck Sharp Dohme (MSD). Available products include the combined Measles-Mumps-Rubella (MMR) vaccines such as Priorix, MMR II, and Priorix Tetra. Some medical experts, including internal medicine specialists, have noted that certain approved vaccines, particularly from Bio Farma, could provide a more affordable alternative for adult immunization.
To ensure efficient distribution and prevent wastage, the Ministry of Health is utilizing the SMILE monitoring system via Satu Sehat Logistik. This platform allows officials to track vaccine availability in real-time from the provincial level down to community health centers (Puskesmas) and other healthcare facilities. As of the 13th week of 2026, national stocks of the MR vaccine stand at 9.8 million doses, which is estimated to be sufficient for the next 5.5 months.
This expansion of vaccination eligibility underscores the critical need to protect healthcare infrastructure during outbreaks, ensuring that those providing care remain healthy and capable of managing the public health crisis.
